This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A look at REL-1017 ahead of the RELIANCE III results
Ticker(s): RLMDWho's the expert?
Institution: Private Practice
- Board certified in Adult and Adolescent Psychiatry .
- Experiences include inpatient and outpatient care with interests in psychopharmacotherapy, adolescent psychiatry, women’s mental health issues, compulsive gambling, and brain stimulation techniques (ECT, VNS & TMS) in the treatment of resistant mood disorders.
- Referred 8 patients for Spravato and Ketamine infusions.
- Familiar with Phase 2 Trial of Psilocybin for Treatment-Resistant Depression from Compass Pathways.
Interview GoalDiscuss with a psychiatrist their opinion on REL-1017 as a monotherapy in treating MDD
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
